Nicolas Mach
About
Nicolas Mach is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Immunology.
According to data from OpenAlex, Nicolas Mach has authored 96 papers receiving a total of 3.1k indexed citations (citations by other indexed papers that have themselves been cited), including 50 papers in Oncology, 30 papers in Pulmonary and Respiratory Medicine and 26 papers in Immunology. Recurrent topics in Nicolas Mach's work include Cancer Immunotherapy and Biomarkers (27 papers), Immunotherapy and Immune Responses (22 papers) and CAR-T cell therapy research (19 papers). Nicolas Mach is often cited by papers focused on Cancer Immunotherapy and Biomarkers (27 papers), Immunotherapy and Immune Responses (22 papers) and CAR-T cell therapy research (19 papers). Nicolas Mach collaborates with scholars based in Switzerland, United States and Italy. Nicolas Mach's co-authors include Glenn Dranoff, Silke Gillessen, Martín C. Mihm, S. Brian Wilson, C. Sheehan, Richard C. Mulligan, Chris S. Lantz, Stephen J. Galli, Yukifumi Nawa and Chang Ho Song and has published in prestigious journals such as Nature, New England Journal of Medicine and Proceedings of the National Academy of Sciences.
In The Last Decade
Nicolas Mach
93 papers receiving 3.1k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Nicolas Mach Switzerland | 25 | 1.6k | 1.2k | 553 | 434 | 330 | 96 | 3.1k | ||
| Bruce Allen Bach United States | 25 | 1.1k 0.7× | 659 0.6× | 499 0.9× | 600 1.4× | 184 0.6× | 57 | 2.7k | ||
| Voravit Ratanatharathorn United States | 29 | 1.1k 0.7× | 857 0.7× | 350 0.6× | 234 0.5× | 265 0.8× | 140 | 3.6k | ||
| Mélissa Dullaers Belgium | 29 | 2.5k 1.6× | 524 0.5× | 816 1.5× | 188 0.4× | 241 0.7× | 45 | 3.6k | ||
| Shaun R. McCann Ireland | 28 | 537 0.3× | 898 0.8× | 322 0.6× | 311 0.7× | 263 0.8× | 107 | 2.9k | ||
| Vincent R. Bonagura United States | 33 | 1.6k 1.0× | 447 0.4× | 637 1.2× | 372 0.9× | 221 0.7× | 133 | 3.3k | ||
| Shuichi Taniguchi Japan | 40 | 1.7k 1.1× | 1.8k 1.6× | 1.0k 1.8× | 388 0.9× | 406 1.2× | 275 | 6.1k | ||
| Lukas Flatz Switzerland | 29 | 1.6k 1.0× | 1.8k 1.6× | 721 1.3× | 542 1.2× | 210 0.6× | 102 | 4.0k | ||
| E Naparstek Israel | 24 | 1.9k 1.2× | 1.5k 1.3× | 395 0.7× | 196 0.5× | 207 0.6× | 65 | 5.3k | ||
| Aks Chiang Hong Kong | 35 | 833 0.5× | 1.7k 1.5× | 457 0.8× | 151 0.3× | 231 0.7× | 121 | 3.0k | ||
| George E. Sale United States | 37 | 2.1k 1.3× | 1.7k 1.5× | 680 1.2× | 857 2.0× | 624 1.9× | 97 | 7.4k |
Countries citing papers authored by Nicolas Mach
Since
Specialization
Citations
This map shows the geographic impact of Nicolas Mach's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nicolas Mach with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nicolas Mach more than expected).
Fields of papers citing papers by Nicolas Mach
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Nicolas Mach. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nicolas Mach. The network helps show where Nicolas Mach may publish in the future.
Co-authorship network of co-authors of Nicolas Mach
This figure shows the co-authorship network connecting the top 25 collaborators of Nicolas Mach. A scholar is included among the top collaborators of Nicolas Mach based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nicolas Mach. Nicolas Mach is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
McKee, Thomas, Nicolas Mach, Kaveh Samii, et al.. (2024). Effectiveness of fractionated rituximab in preventing tumor lysis syndrome in aggressive B‐ cell lymphoma: Insights from real‐life clinical practice. Cancer Reports. 7(10). e1983–e1983.
2.
Lin, Chia‐Chi, Giuseppe Curigliano, Armando Santoro, et al.. (2024). Sabatolimab in combination with spartalizumab in patients with non-small cell lung cancer or melanoma who received prior treatment with anti-PD-1/PD-L1 therapy: a phase 2 multicentre study. BMJ Open. 14(8). e079132–e079132.
3.
Fernández, Eugenio, Denis Migliorini, Emily Charrier, et al.. (2024). A First-in-Human Phase I Clinical Study with MVX-ONCO-1, a Personalized Active Immunotherapy, in Patients with Advanced Solid Tumors. Cancer Research Communications. 4(8). 2089–2100.
4.
Zilli, Thomas, Ciro Franzese, Matthias Gückenberger, et al.. (2024). ONE SHOT - single shot radiotherapy for localized prostate cancer: 18-month results of a single arm, multicenter phase I/II trial. Radiotherapy and Oncology. 194. 110181–110181.
5.
Mach, Nicolas, et al.. (2023). LBA46 SAKK 11/16, a phase IIa trial evaluating overall survival (OS) for recurrent/metastatic Head & neck squamous cell carcinoma (RMHNSCC) patients (pts) progressing after ≥ 1 line of systemic therapy, treated with MVX-ONCO-1, a novel, first in class cell encapsulation-based immunotherapy. Annals of Oncology. 34. S1286–S1286.
6.
Bordry, Natacha, Anne‐Claire Mamez, Sabine Yerly, et al.. (2023). SARS-CoV-2 m-RNA Vaccine Response in Immunocompromised Patients: A Monocentric Study Comparing Cancer, People Living with HIV, Hematopoietic Stem Cell Transplant Patients and Lung Transplant Recipients. Vaccines. 11(8). 1284–1284.
7.
Mach, Nicolas, Carmen Belli, Eduardo Fernández, et al.. (2023). 1037P Phase I dose-escalation trial with tumor-targeted interleukin-12 (IL12-L19L19) in patients with solid tumors. Annals of Oncology. 34. S629–S630.
8.
Joerger, Markus, Yannis Metaxas, Khalil Zaman, et al.. (2022). Outcome and Prognostic Factors of COVID-19 Infection in Swiss Cancer Patients: Final Results of SAKK 80/20 (CaSA). Cancers. 14(9). 2191–2191.
9.
Reis, Daniela, et al.. (2022). Complementary and Integrative Medicine in Pediatric Oncology – Development and Evaluation of a Blended Learning Program. Klinische Pädiatrie. 234(3). 163–168.
10.
Curigliano, Giuseppe, Hans Gelderblom, Nicolas Mach, et al.. (2021). Phase I/Ib Clinical Trial of Sabatolimab, an Anti–TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti–PD-1 Antibody, in Advanced Solid Tumors. Clinical Cancer Research. 27(13). 3620–3629.
11.
Charrier, Emily, et al.. (2021). A Functional GM-CSF Receptor on Dendritic Cells Is Required for Efficient Protective Anti-Tumor Immunity. SHILAP Revista de lepidopterología. 1(3). 240–252.
12.
Charrier, Emily, et al.. (2021). Local Sustained GM-CSF Delivery by Genetically Engineered Encapsulated Cells Enhanced Both Cellular and Humoral SARS-CoV-2 Spike-Specific Immune Response in an Experimental Murine Spike DNA Vaccination Model. Vaccines. 9(5). 484–484.
13.
Charrier, Emily, et al.. (2021). A Quantitative ELISA Protocol for Detection of Specific Human IgG against the SARS-CoV-2 Spike Protein. Vaccines. 9(7). 770–770.
14.
Harrington, Kevin J., Anthony Kong, Nicolas Mach, et al.. (2020). Talimogene Laherparepvec and Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (MASTERKEY-232): A Multicenter, Phase 1b Study. Clinical Cancer Research. 26(19). 5153–5161.
15.
Rothschild, Sacha I., Alfred Zippelius, E.I. Eboulet, et al.. (2020). 1237MO SAKK 16/14: Anti-PD-L1 antibody durvalumab in addition to neoadjuvant chemotherapy in patients with stage IIIA (N2) non-small cell lung cancer (NSCLC) – A multicenter single-arm phase II trial. Annals of Oncology. 31. S803–S804.
16.
Curioni‐Fontecedro, Alessandra, Jean Yannis Perentes, Hans Gelpke, et al.. (2019). Preoperative chemotherapy and radiotherapy concomitant to cetuximab in resectable stage IIIB NSCLC: a multicentre phase 2 trial (SAKK 16/08). British Journal of Cancer. 120(10). 968–974.
17.
Siano, Marco, Vittoria Espeli, Nicolas Mach, et al.. (2018). Gene signatures and expression of miRNAs associated with efficacy of panitumumab in a head and neck cancer phase II trial. Oral Oncology. 82. 144–151.
18.
Groß, Stefanie, Volker Lennerz, Elisa Gallerani, et al.. (2015). Short Peptide Vaccine Induces CD4+ T Helper Cells in Patients with Different Solid Cancers. Cancer Immunology Research. 4(1). 18–25.
19.
Aïssa, Assma Ben, et al.. (2011). [b]Anticancéreux[/b] sous haute tension. Revue Médicale Suisse. 7(308). 1761–1766.
20.
Schwenter, Frank, et al.. (2008). Development Of A Cell Encapsulation Approach For Human Anti-Tumor Immunotherapy. The International Journal of Artificial Organs. 31(7). 601–601.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Bruce Allen Bach Breakdown of academic impact, for papers by Voravit Ratanatharathorn Breakdown of academic impact, for papers by Mélissa Dullaers Breakdown of academic impact, for papers by Shaun R. McCann Breakdown of academic impact, for papers by Vincent R. Bonagura Breakdown of academic impact, for papers by Shuichi Taniguchi Breakdown of academic impact, for papers by Lukas Flatz Breakdown of academic impact, for papers by E Naparstek Breakdown of academic impact, for papers by Aks Chiang Breakdown of academic impact, for papers by George E. Sale